B. Whitehead

Statistics

Publications

Citations

287

H-Index

Active since

2004

Affiliations

Research Triangle Park Foundation(Current)

Case Western Reserve University

GlaxoSmithKline (Netherlands)

Duke Medical Center

GlaxoSmithKline (United States)

B. Whitehead is an author at Research Triangle Park Foundation specializing in pharmacology, tyrosine kinase inhibitor pharmacokinetics, and tyrosine kinase inhibitor therapy.

Publications per year

2004–2011

Publications

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

Kevin M. Koch, Nandi J. Reddy, Roger B. Cohen et al. · Journal of Clinical Oncology · 2009 · 138 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +13

Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors

Herbert I. Hurwitz, Afshin Dowlati, S. Savage et al. · Journal of Clinical Oncology · 2005 · 74 citations

Medicine, Pharmacology, Clinical Pharmacology +1

Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors

A. Benjamin Suttle, H. Hurwitz, Afshin Dowlati et al. · Journal of Clinical Oncology · 2004 · 23 citations

Pharmacy, Oncology, Pharmacology +13

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently

Maja J.A. deJonge, S. Savage, Jaap Verweij et al. · Journal of Clinical Oncology · 2006 · 22 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Are neurocognitive speed and inconsistency similarly affected in type 2 diabetes?

B. Whitehead, Roger A. Dixon, David F. Hultsch et al. · Journal of Clinical and Experimental Neuropsychology · 2011 · 18 citations · Full text

Medicine, Neurology, Neuroscience +14

1–5 of 6